Posted by Michael Wonder on 03 Jun 2025
Zealand Pharma submits marketing authorisation application to the EMA for glepaglutide in short bowel syndrome
2 June 2025 - Zealand Pharma today announced the submission of a marketing authorisation application to the EMA for glepaglutide, a long-acting GLP-2 analog, for the treatment of adult patients with short bowel syndrome.
The submission of the marketing authorisation application to the EMA for glepaglutide administered twice weekly for the treatment of short bowel syndrome is based on results from a pivotal Phase 3 trial (EASE-1), supported by interim results from two on-going long-term extension trials (EASE-2 and EASE-3) and results from a mechanistic trial (EASE-4).
